

**HEALTH TECHNOLOGY APPRAISAL: NICE Health Technology Appraisal -
Appraisal Consultation Document (ACD)**

On topotecan for second line treatment of small cell lung cancer

TO: NICE

**FROM: NHS Quality Improvement
Scotland**

1. This NICE appraisal is identical to the previous SMC decision on oral topotecan and would not lead to any change in practice in Scotland. We already are using oral topotecan where appropriate in clinical practice.

The advice on not using intravenous topotecan creates challenges for the ongoing clinical trial of IV topotecan versus IV amrubicin but that is an issue for the investigators of that trial.



2. No comment from Professor Allan Price.

29 July 2009